EP1744764A1 — Liposomal formulations of anthracycline agents and cytidine analogs
Assigned to Jazz Pharmaceuticals Therapeutics Inc · Expires 2007-01-24 · 19y expired
What this patent protects
Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in a liposomal carrier. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the g…
USPTO Abstract
Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in a liposomal carrier. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carrier are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.
Drugs covered by this patent
- Cytarabine (Cytarabine) · Nippon Shinyaku Co., Ltd.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.